Artiva Biotherapeutics
Artiva is a biotechnology company focused on developing NK cell-based therapies for autoimmune diseases and cancers. They are engaged in advancing clinical trials for their innovative treatments, including off-the-shelf NK cell therapies. The company emphasizes a collaborative and innovative work environment aimed at improving patient outcomes.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2019
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases. Their lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) across multiple clinical trials, including basket trials in rheumatoid arthritis and Sjögren's disease. The company leverages highly scaled, off-the-shelf, allogeneic NK cell manufacturing to make cell therapies broadly accessible to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Artiva Biotherapeutics.
Senior Director/Executive Director, Head of GCP Quality Assurance
Nkarta, Inc.
Senior Director, Quality Assurance GCP
Cogent Biosciences
Clinical Site Liaison
Vor Bio
Associate Clinical Project Manager
Zenas BioPharma
Senior Clinical Trial Associate, Pulmovant
Pulmovant
Vice President, Clinical Operations, US
Immatics